A new hepatitis drug could be significant for Arrowhead Research, CEO Chris Anzalone says.» Read More
Amgen Inc. rose $6.70 or 5.4 percent, to $130.01. Biogen Idec rose $2.79 or. 8 percent, to $344.52. Celgene Corp. rose$. 61 or. 7 percent, to $88.34.
Amgen Inc. rose $6.40 or 5.2 percent, to $129.71. Biogen Idec rose $2.63 or. 8 percent, to $344.36. Celgene Corp. rose $1.33 or 1.5 percent, to $89.06.
July 30- U.S. health insurer Humana Inc reported a lower profit owing to higher costs on Wednesday, as mounting concerns about increased medical spending drove health insurance industry shares lower for a second straight day.
Amgen Inc. rose $6.70 or 5.4 percent, to $130.01. Biogen Idec rose $4.40 or 1.3 percent, to $346.13. Celgene Corp. rose $1.63 or 1.9 percent, to $89.36.
July 30- U.S. health insurer Humana Inc said on Wednesday that second-quarter profit fell due to investments in the exchanges created under President Barack Obama's healthcare reform law as well as costly new hepatitis C drug treatments. Humana said membership growth and a lower share count due to stock buybacks had helped offset some of the new costs.
July 29- Aetna Inc, the third-largest U.S. health insurer, reported a rise in medical costs on Tuesday, raising investor concerns that a long run of low growth in such costs might be ending and pushing shares in the industry lower.
NEW YORK, July 29- With some of Wall Street's more volatile names set to report in the next couple of days, traders who bet on big swings in shares are hoping to see moves more like Facebook than Netflix. Netflix, along with Gilead Sciences and several other stocks famous for their sharp gyrations, were unusually calm following their latest quarterly reports.
WASHINGTON— A $1,000- per-pill drug that insurers are reluctant to pay for has quickly become the treatment of choice for a liver-wasting viral disease that affects more than 3 million Americans. In less than six months, prescriptions for Sovaldi have eclipsed all other hepatitis C pills combined, according to new data from IMS Health.
Amgen Inc. fell$. 19 or. 2 percent, to $122.65. Biogen Idec rose$. 94 or. 3 percent, to $336.39. Celgene Corp. rose$. 48 or. 6 percent, to $87.64.
Amgen Inc. fell$. 84 or. 7 percent, to $122.00. Biogen Idec fell$. 40 or. 1 percent, to $335.05. Celgene Corp. fell$. 19 or. 2 percent, to $86.97.
Amgen Inc. fell$. 67 or. 5 percent, to $122.17. Biogen Idec fell$. 97 or. 3 percent, to $334.48. Celgene Corp. fell$. 48 or. 6 percent, to $86.68.
LONDON, July 25- Two new leukemia drugs from Johnson& Johnson and Gilead Sciences have been recommended for approval by European regulators, paving the way for formal approval in a couple of months. The European Medicines Agency said on Friday its experts had issued positive opinions for J&J's ibrutinib, developed with Pharmacyclics, and Gilead's idelalisib.
Amgen Inc. rose$. 25 or. 2 percent, to $122.26. Biogen Idec fell$. 81 or. 2 percent, to $336.79. Celgene Corp. fell $2.93 or 3.3 percent, to $86.19.
Apple Inc. fell. 2 percent to $97.03 with 44,545,900 shares traded. Ariad Pharmaceuticals Inc. rose 5.2 percent to $6.18 with 26,030,200 shares traded. BlackBerry Ltd. rose 5.6 percent to $10.38 with 31,147,300 shares traded.
Biogen Idec fell$. 94 or. 3 percent, to $336.66. Celgene Corp. fell $3.22 or 3.6 percent, to $85.90. Gilead Sciences Inc. rose$. 04 or percent, to $90.38.
July 24- Celgene Corp reported a 25 percent rise in second-quarter profit, edging out Wall Street expectations, but a raised 2014 forecast failed to excite investors and its shares fell nearly 4 percent.
Amgen Inc. fell$. 51 or. 4 percent, to $121.50. Biogen Idec rose$. 29 or. 1 percent, to $337.89. Celgene Corp. fell $3.63 or 4.1 percent, to $85.49.
July 23- Gilead Sciences Inc said on Wednesday that its new hepatitis C drug Sovaldi had sales of $3.5 billion in the second quarter, demonstrating that the furor over its price has not curtailed early use. Since its December launch, Sovaldi has been prescribed for more than 80,000 patients in the United States and Europe, the company said.
If you have a penchant for quizzes and such, Jim Cramer thinks this question could lead you to a solid stock idea.
Check out which companies are making headlines after the bell Wednesday: Facebook, AT&T, Gilead & more.